Physician profile
Scott Wayne Sterling
NPI 1154384170
$1,343.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $407 · 2021: $287 · 2022: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $706.65 | 2019-2022 | |
| Gilead Sciences, INC. | $152.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $140.86 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.64 | 2020-2022 | |
| Novo Nordisk INC | $91.68 | 2020-2021 | |
| Lilly USA, LLC | $38.15 | 2020-2022 | |
| Biogen, INC. | $26.72 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $15.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.40 | 2021 | |
| Merck Sharp & Dohme LLC | $15.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.87 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.